Clinical Trial Update: Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect of VI-0521 (Qsymia) on glomerular filtration rate in overweight or obese healthy adults; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Qsymia (phentermine/topiramate)

Snippet

Sponsor: VIVUS LLC | Conditions: Obesity | Phase 4 | Status: COMPLETED | Results posted: 2016-02-09